MGMT and neoplasm: Furthermore, LPHNs nanocarriers loaded with CRISPR/Cas9 plasmids targeting the MGMT gene and modified with the cyclic arginine-glycine-aspartic-conjugated (cRGD) peptide (which targets the overexpressed integrin αvβ3 receptors in tumor cells) were successfully synthesized and demonstrated the ability to protect pCas9/MGMT from enzymatic degradation.